The majority of patients with metastatic melanoma will exhibit brain metastases, which are the most common cause of death. Effective systemic treatment options are now available. Treatment planning and therapeutic interventions should be carried out with an interdisciplinary and multi-modal approach. Current clinical studies for melanoma patients with brain metastases are investigating new treatment options such as PD-1 -antibodies, combined ipilimumab and nivolumab, combined BRAF inhibitors and MEK inhibitors, and stereotactic radiation in combination with immunotherapy or targeted therapy.